These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26904699)

  • 1. Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens.
    Weeks AC; Kimple ME
    J Investig Med High Impact Case Rep; 2015; 3(3):2324709615603199. PubMed ID: 26904699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An exceptionally severe hyperuricemia in acute renal failure caused by spontaneous tumor lysis syndrome (TLS)].
    Basile C; Montanaro A
    G Ital Nefrol; 2003; 20(5):525-8. PubMed ID: 14634969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
    Alakel N; Middeke JM; Schetelig J; Bornhäuser M
    Onco Targets Ther; 2017; 10():597-605. PubMed ID: 28203093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
    Dinnel J; Moore BL; Skiver BM; Bose P
    Core Evid; 2015; 10():23-38. PubMed ID: 25610345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous Tumor Lysis Syndrome Secondary to Metastatic Small Cell Lung Cancer.
    Koura S; Parekh V; Parikh AD; Kaur K; Dunn BK
    Cureus; 2023 Feb; 15(2):e34557. PubMed ID: 36879689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasburicase for the management of tumor lysis syndrome in neonates.
    McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
    Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
    Shukla DK; Gupta D; Aggarwal A; Kumar D
    Indian J Med Paediatr Oncol; 2017; 38(3):360-362. PubMed ID: 29200691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol.
    Gartenberg A; Winkel M; Leonard N
    Am J Emerg Med; 2024 Apr; 78():242.e1-242.e3. PubMed ID: 38007380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.